cas 646066-59-3, XLI 093 | Articles data

Articles about 646066-59-3Total 3 be found

Synthesis, in Vitro Affinity, and Efficacy of a Bis 8-Ethynyl-4H-imidazo[1,5a]-[1,4]benzodiazepine Analogue, the First Bivalent α5 Subtype Selective BzR/GABAA Antagonist
The synthesis and in vitro affinity of the α5β3γ2 (α5) subtype selective BzR/GABAA antagonist 7 is described. This ligand is selective for α5 subtypes in vitro and is a potent antagonist of the effects of diazepam only at α5β3γ2 subtypes (oocytes). Ligands such as 7 will be important in the determination of which physiological function(s) are subserved by this GABAA α5 subtype.
Li, Xiaoyan,Cao, Hui,Zhang, Chunchun,Furtmueller, Roman,Fuchs, Karoline,Huck, Sigismund,Sieghart, Werner,Deschamps, Jeffrey,Cook, James M.
p. 5567 - 5570
(2003)
Read Online

A study of the structure-activity relationship of GABAA-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis
The stable conformations of GABAA-benzodiazepine receptor bivalent ligands were determined by low temperature NMR spectroscopy and confirmed by single crystal X-ray analysis. The stable conformations in solution correlated well with those in th
Han, Dongmei,Holger Foersterling,Li, Xiaoyan,Deschamps, Jeffrey R.,Parrish, Damon,Cao, Hui,Rallapalli, Sundari,Clayton, Terry,Teng, Yun,Majumder, Samarpan,Sankar, Subramaniam,Roth, Bryan L.,Sieghart, Werner,Furtmuller, Roman,Rowlett, James K.,Weed, Michael R.,Cook, James M.
experimental part
p. 8853 - 8862
(2009/04/11)

GABAERGIC AGENTS TO TREAT MEMORY DEFICITS
The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognizance. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.
-
Page/Page column 30-31; sheet 1

(2008/06/13)